comparemela.com

Latest Breaking News On - Covaxin study - Page 1 : comparemela.com

Covaxin Safe, Well-Tolerated in 2-18 Years Age-group: Bharat Biotech

A press release from the vaccine maker said a phase II/III study has been accepted and published in The Lancet Infectious Diseases, a peer-reviewed, high-impact factor journal.

Andhra pradeshKrishna ellaBharat biotech international limitedCentral drugs standard control organisationThelancet infectious diseasesBharat biotechBharat biotech covaxinBharat biotech vaccineCovaxin clinical trialCovaxin studyCovaxin trialCovid 19Covid 19 childrenCovid 19 vaccineLancet infectious diseasesThe lancet

Covaxin trial results for 2-18 age group pave way for inoculation of kids

Bharat Biotech said that Covaxin has proven to be safe, well-tolerated, and immunogenic in paediatric subjects in phase II/III study.

Andhra pradeshUnited statesUnited kingdomZydus cadila zycoVispi jokhiKrishna ellaUnion health ministryBharat biotechManaging directorLav agarwalJoint secretaryUnion healthZydus cadilaCovid 19 vaccineOvid 19 newsBharat biotech

Covaxin found safe, well-tolerated, and immunogenic in 2-18 age group: Bharat Biotech

Bharat Biotech explained that 374 subjects reported either mild or moderate severity symptoms with 78.6 per cent getting resolved within 1 day.

Andhra pradeshKrishna ellaCentral drugs standard control organisationBharat biotechManaging directorCovid 19 vaccineOvid 19 newsBharat biotechHarat biotech covaxninCovaxin studyTudy covaxin childrenOvaxin 2 18 year oldsCovaxin trials

Hafta 334: Covaxin, Yoga Day, Modi meets J&K politicians

The podcast where we discuss the news of the week.

Jammu and kashmirHong kongJammin raoJayashree arunachalamManisha pandeAbhinandan sekhriNarendra modiRaman kirpalInternational yoga dayBharat biotechApple dailyCovaxin studyCovix phase 3 dataModi gupkar alliance meetingModi kashmir meetingYoga dal vaccination

vimarsana © 2020. All Rights Reserved.